- Home
- MOBX vs MAIA Comparison
MOBX vs MAIA Comparison
Compare MOBX & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- MAIA
- Stock Information
- Founded
- MOBX 2020
- MAIA 2018
- Country
- MOBX United States
- MAIA United States
- Employees
- MOBX N/A
- MAIA N/A
- Industry
- MOBX
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- MAIA Health Care
- Exchange
- MOBX Nasdaq
- MAIA Nasdaq
- Market Cap
- MOBX 52.0M
- MAIA 44.9M
- IPO Year
- MOBX N/A
- MAIA 2022
- Fundamental
- Price
- MOBX $0.68
- MAIA $1.24
- Analyst Decision
- MOBX
- MAIA
- Analyst Count
- MOBX 0
- MAIA 0
- Target Price
- MOBX N/A
- MAIA N/A
- AVG Volume (30 Days)
- MOBX 1.8M
- MAIA 911.3K
- Earning Date
- MOBX 12-18-2025
- MAIA 11-07-2025
- Dividend Yield
- MOBX N/A
- MAIA N/A
- EPS Growth
- MOBX N/A
- MAIA N/A
- EPS
- MOBX N/A
- MAIA N/A
- Revenue
- MOBX $10,984,000.00
- MAIA N/A
- Revenue This Year
- MOBX N/A
- MAIA N/A
- Revenue Next Year
- MOBX N/A
- MAIA N/A
- P/E Ratio
- MOBX N/A
- MAIA N/A
- Revenue Growth
- MOBX 180.13
- MAIA N/A
- 52 Week Low
- MOBX $0.55
- MAIA $1.22
- 52 Week High
- MOBX $2.47
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- MOBX 36.82
- MAIA 36.27
- Support Level
- MOBX $0.65
- MAIA $1.26
- Resistance Level
- MOBX $0.75
- MAIA $1.57
- Average True Range (ATR)
- MOBX 0.07
- MAIA 0.10
- MACD
- MOBX -0.02
- MAIA -0.02
- Stochastic Oscillator
- MOBX 10.92
- MAIA 5.71
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.